Polyrizon (NASDAQ:PLRZ) has announced the filing of a patent application for its advanced intranasal drug delivery system Trap & Target (T&T) technology, with the Israel Patent Office (ILPO).
The company stated that this application aligns with its recent U.S. application, which includes its nasal blocker technology, Capture and Contain (C&C), alongside T&T.
Tomer Izraeli, CEO of Polyrizon, remarked, “The filing of this divisional patent application for our T&T platform marks another important step in strengthening our global intellectual property portfolio. We believe that the T&T platform has the potential to transform intranasal drug delivery by improving the efficacy and safety of a wide range of medications. We are committed to advancing this innovative technology to address critical healthcare challenges and improve patient outcomes.”
